期刊
STEM CELLS
卷 38, 期 1, 页码 146-159出版社
OXFORD UNIV PRESS
DOI: 10.1002/stem.3077
关键词
-
资金
- CHU de Toulouse (Appel d'offre local 2008)
- Etablissement Francais du Sang (APR 2016)
- Infrastructure program EcellFRANCE [ANR-11-INSB-005]
- European Center for Transplantation Sciences and Immunotherapy (IHU CESTI) [ANR-10-IHUB-0005]
- French National Cancer Institute [INCa PLBIO-17-219]
- Labex IGO [ANR-11-LABX-0016-01]
- Region Bretagne
Clinical-grade mesenchymal stromal cells (MSCs) can be expanded from bone marrow and adipose tissue to treat inflammatory diseases and degenerative disorders. However, the influence of their tissue of origin on their functional properties, including their immunosuppressive activity, remains unsolved. In this study, we produced paired bone marrow-derived mesenchymal stromal cell (BM-MSC) and adipose-derived stromal cell (ASC) batches from 14 healthy donors. We then compared them using transcriptomic, phenotypic, and functional analyses and validated our results on purified native MSCs to infer which differences were really endowed by tissue of origin. Cultured MSCs segregated by their tissue of origin, based on their gene expression profile, were analyzed using differential expression and weighted gene coexpression network analysis. This translated into distinct immune-related gene signatures, phenotypes, and functional cell interactions. Importantly, sorted native BM-MSCs and ASCs essentially displayed the same distinctive patterns as their in vitro-expanded counterparts. As a whole, ASCs exhibited an immune profile consistent with a stronger inhibition of immune response and a lower immunogenicity, supporting the use of adipose tissue as a valuable source for clinical applications. Stem Cells 2019
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据